Article metrics

Download PDFPDF
LB0005 12-week results of a phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional dmards in patients with rheumatoid arthritis

 

Online download statistics by month:

Online download statistics by month: February 2014 to March 2024

AbstractFullPdf
Feb 20141401
Mar 2014802
Apr 20142712
May 20141602
Jun 20141701
Jul 2014802
Aug 20141301
Sep 2014800
Oct 2014400
Nov 2014400
Dec 2014400
Jan 2015200
Feb 2015600
Mar 2015601
Apr 20152600
May 20151401
Jun 2015600
Jul 2015300
Aug 2015500
Sep 2015701
Oct 2015801
Nov 20151302
Dec 20151901
Jan 2016903
Feb 2016900
Mar 2016801
Apr 2016201
May 20161706
Jun 20161804
Jul 20162204
Aug 2016801
Sep 2016912
Oct 20161503
Nov 20161101
Dec 20161804
Jan 20172507
Feb 2017800
Mar 20171803
Apr 20171600
May 20171301
Jun 20172101
Jul 20171200
Aug 20173601
Sep 20174802
Oct 20172600
Nov 20171801
Dec 20172000
Jan 20184003
Feb 2018400
Mar 20182201
Apr 20181400
May 20182000
Jun 2018600
Jul 2018400
Aug 2018600
Sep 20181000
Oct 20181000
Nov 20181800
Dec 20181200
Jan 2019400
Feb 2019600
Mar 2019800
Apr 2019401
May 2019200
Jun 20191201
Jul 2019701
Aug 2019602
Sep 2019400
Oct 20191100
Nov 2019200
Dec 2019200
Feb 20201701
Apr 20201802
May 20202602
Jun 2020800
Jul 20201701
Sep 20201801
Oct 2020900
Nov 20202702
Dec 2020602
Jan 2021600
Mar 2021200
Apr 20212700
May 2021400
Jun 2021500
Aug 2021200
Oct 2021600
Nov 20211501
Dec 20212601
Jan 20221901
Feb 2022800
Mar 2022800
Apr 20221000
May 20221301
Jun 2022300
Jul 20222500
Aug 20221100
Sep 20221001
Oct 20222000
Nov 20221400
Dec 20221200
Jan 20231200
Feb 20234501
Mar 2023700
Apr 2023900
May 2023400
Jun 2023400
Jul 20231200
Aug 2023600
Sep 20231001
Oct 20231301
Nov 2023400
Dec 2023800
Jan 20241000
Feb 20241201
Mar 20241000
Total1437293